News Aubagio Becomes 1st Once-daily Oral DMT for Relapsing MS Patients in India Aubagio Becomes 1st Once-daily Oral DMT for Relapsing MS Patients in India by Jose Marques Lopes, PhD | December 7, 2018 Share this article: Share article via email Copy article link AubagioĀ (teriflunomide) has become the first once-a-day, oral disease-modifying therapy (DMT) for multiple sclerosis (MS) to be approved for use inĀ India. Sanofi Genzymeās therapy is indicated for first-line treatment of relapsing MS. It should be taken each day with or without food, and patients in India will have access to Aubagio tablets at a 14 mg dose each. “This product has the potential to offer an efficacious and convenient treatment regimen … vis-Ć -vis common treatment options that are injectables,” N. Rajaram, MD, Sanofi Indiaās managing director, said in aĀ press release.”Ā With AubagioĀ (teriflunomide, 14 mg), we reiterate Sanofi Genzyme’s commitment to improve and empower the lives of people with debilitating diseases inĀ India.” According to theĀ Multiple Sclerosis Society of India, more than 200,000 people are living with MS in the country. Rajaram mentioned that greater awareness of the disease and access to better diagnostic facilities have led to an increase in MS diagnoses in India. According to Sanofi Genzyme, Aubagio has nearly 13 years of proven clinical efficacy, safety, and tolerability data. The medication works by blocking an enzyme called dihydroorotate dehydrogenase, which is key for the proliferation and maturation of immune T- and B-cells. Both these cells are involved in inflammatory reactions believed to induce loss of the protective myelin layer (the hallmark of MS), with subsequent damage in nerve fibers. āWhen taken daily, AubagioĀ (teriflunomide, 14 mg)Ā reduces the number of overactive immune cells that cause the disease flare-ups, while still allowing normal immune cell activity to occur,” said Shalini Menon, MD, Sanofiās head of medical affairs for IndiaĀ &Ā South Asia. Menon also highlighted results from studies showing Aubagioās consistent efficacy in “reducing relapse frequency, delaying the accumulation of physical disability and arresting further decrease in brain volume.” Also, āgiven its convenience as an oral medicine,ā Menon added, Aubagio āencourages people with multiple sclerosis to continue with long-term treatment.” Aubagio was approved by the U.S. Food and Drug Administration in 2012, and by the European Comission in 2013. The therapy is now available in more than 81 countries. Print This Page About the Author Jose Marques Lopes, PhD JosĆ© holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimerās disease, he moved on in 2016 to a career in science writing and communication. JosĆ© is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings. Tags Aubagio, Sanofi Genzyme, teriflunomide
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8